Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

13.03
+0.02000.15%
Post-market: 12.95-0.0800-0.61%16:10 EDT
Volume:361.18K
Turnover:4.70M
Market Cap:1.37B
PE:-8.41
High:13.22
Open:13.11
Low:12.86
Close:13.01
Loading ...

Edgewise Therapeutics Shares Down 32.9% After Mid-Stage Trial Data of Co's Heart Disease Drug

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics 9.935M share Spot Secondary priced at $20.13

TIPRANKS
·
02 Apr

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of US Tariffs Announcement

MT Newswires Live
·
02 Apr

Morning Brew: Folksam Divests Tesla Amid Labor Concerns

GuruFocus
·
02 Apr

Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing

Dow Jones
·
02 Apr

Edgewise Therapeutics Reports New Results From Phase 2 Hypertrophic Cardiomyopathy Trial

MT Newswires Live
·
02 Apr

Edgewise Therapeutics Prices $200 Million Offering

MT Newswires Live
·
02 Apr

BRIEF-Edgewise Therapeutics Announces Pricing Of $200 Million Underwritten Offering Of Common Stock

Reuters
·
02 Apr

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

PR Newswire
·
02 Apr

BRIEF-Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy

Reuters
·
02 Apr

Edgewise: Trial Showed Clinically Meaningful Reductions in Lvot Gradients in Participants With Obstructive HCM

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics Inc - Edg-7500 Was Generally Well-Tolerated

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 Cirrus-HCM Four-Week Trial of Edg-7500 in Hypertrophic Cardiomyopathy (HCM)

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics Inc: Initial Data Read-Out From Part D Is Expected in Second Half of 2025

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics Inc - Phase 3 Initiation Planned for First Half of 2026

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

PR Newswire
·
27 Mar

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Business Wire
·
11 Mar

Stock Track | Edgewise Therapeutics, Inc. (EWTX) Soars 5.33% on Analyst Optimism

Stock Track
·
07 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edgewise Therapeutics (EWTX) and Walgreens Boots Alliance (WBA)

TIPRANKS
·
07 Mar